## **VA COOPERATIVE STUDY #578**

Participant ID:		

			FORM 15: HOSPITALIZATIONS WITHIN 96 HOURS POST PROCEDURE		
foll ho:	owin spita	ig thei I withi	eted by study personnel via medical record review for participants who remain hospitalized beyond 12 hours r index angiography or for participants who are discharged after their angiography and then readmitted to a n 96 hours. Once completed, this data should be entered into eDC and this form should be filed in the Study Binder.		
1.	Dic	the	participant remain in the hospital (beyond 12 hours) following their index angiography procedure?		
		<b>For</b> r	m15_HospPost12 Blank: -1		
		Yes			
		No	If no, answer Q2 2		
		2.	Was the participant readmitted to a hospital within 96 hours of their index angiography procedure?		
			Readmit Blank: -1		
			☐ Yes (Complete the remaining questions and an Endpoint_SAE Form) 1		
			□ No 2		
	STO	lf Q	1=no and Q2=no, then this form is complete.		
	b	e sen	<b>NDER</b> : All participants are required to have a blood sample collected 96 hours post-angiography to to the Central Laboratory. If the participant remains hospitalized or is readmitted during this time e, the 96 hour blood sample should be collected at the hospital and sent to the Central Laboratory.		
2	Dic	l tha	participant require the use of any IV inotropes during their hospitalization and within 96 hours		
٥.			g their index angiography? (For example, inamrinone (Inocor), milrinone (Primacor), dobutamine)		
InotropeHospPost Blank: -1					
	П	Yes	1		
	П	No	<u>.</u> 2		
		140			
4.	Dic	the	participant require the use of any IV vasodilators during their hospitalization and within 96 hours		
	foll	owing	g their index angiography? (For example, nesiritide (Natrecor) or nitrates/GTN)		
		<mark>Vas</mark>	odilatorHospPost Blank: -1		
		Yes	<mark>1</mark>		
		No	<mark>2</mark>		

5. Did the participant require the use of any IV vasopressors during their hospitalization and within 96 hours following their index angiography? (For example, dopamine (Intropin), phenylephrine (Neosynephrine),

## **VA COOPERATIVE STUDY #578**

		articipant ID:
	nore	inephrine/noradrenalin (Levophed), epinephrine/adrenalin, ephredrine, vasopressin, metarminol
		ate (Aramine)) VasopressorHospPost Blank: -1
		es <mark>1</mark>
		o <mark>2</mark>
6.	Did	e participant experience any episodes of hypotension [defined as systolic blood pressure <90 mmHg
	and	r MAP < 55 mmHg] during their hospitalization and within 96 hours following their index angiography?
		HypoHospPost Blank: -1
		es <mark>1</mark>
		o <mark>2</mark>
7.		e participant require any additional radiological procedures involving contrast administration, including
		ary or non-coronary angiography or computed tomography during their hospitalization and within 96
		following their index angiography?  AddDyeHospPost  Blank: -1
		es If yes, answer Q8.1-Q8.7 for each additional procedure 1  2
	8.1	D
	8.2	Was the additional procedure planned? AddDyeHospPostPlanned Blank: -1
	0.2	□ Yes 1
		□ No 2
	8.3	Which of the following contrast dyes was administered during the additional procedure?
	0.0	AddDyeTypeHospPost Blank: -1
		□ lodixanol (Visipaque) 1
		□ lopamidol (Isovue) 2
		□ lopromide (Ultravist) 3
		□ loversol (Optiray) 4
		and the contract of the contra
		<ul> <li>□ loxaglate (Hexabrix) If checked, answer Q8.5</li> <li>□ lohexol (Omnipaque) If checked, answer Q8.5</li> <li>7</li> </ul>
		and the control of th
		☐ Other contrast dye 8
		(8.4. Specify:AddDyeHospPostOth)  8.5. The contrast dye you noted as administered during the procedure (ioxaglate (Hexabrix) or
		8.5. The contrast dye you noted as administered during the procedure (ioxaglate (Hexabrix) or

SD Worksheet for Form 15 v1.0 Page 2 of 3

iohexol (Omnipaque) has been associated with a higher risk of contrast nephropathy. What

## **VA COOPERATIVE STUDY #578**

	Participant ID:	
	was the reason for choosing this contrast dye type? AddDyeHospPostExplain Blank: -1	
	☐ Only contrast dye available at my facility 1	
	It is the least expensive with comparable safety	
	□ No specific reason <mark>3</mark>	
	□ Other reason <mark>4</mark>	
	(8.6. Please specify: <mark>AddDyeHospPostExplainOth</mark> )	
8.7.	7. What was the total volume of contrast administered during the additional procedure? mls	3
	AddDyeHospPostVol	
	<b>REMINDER</b> : All participants are required to have a blood sample collected 96 hours post-angiography to be sent to the Central Laboratory. If a participant is discharged from the hospital before 96 hours, determine whether he/she will be able to return to the site for this blood draw or, if unable, if the mobile specimen collection service will be required (US participants only).	
	ate Form Completed:F15Complete	

SD Worksheet for Form 15 v1.0 Page 3 of 3